{"id":"W2741345495","doi":"10.1158/1538-7445.am2017-ct039","title":"Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Tolerability; Pharmacokinetics; Immunogenicity; Antibody; Pharmacodynamics; Immunotherapy; CD28; Internal medicine; Cancer; Oncology; Agonist; Pharmacology; T cell; Immunology; Adverse effect; Receptor; Immune system","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001116162,0.001947981,0.002098324,0.0005950876,0.0005223262,0.001115745,0.001048345,0.001196278,0.004298471],"category_scores_gemma":[0.0006601876,0.0005873591,0.001251446,0.0005103377,0.001224388,0.001020929,0.0003221323,0.003672474,0.001242485],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001227361,"about_ca_system_score_gemma":0.002169727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001453788,"about_ca_topic_score_gemma":0.00350578,"domain_scores_codex":[0.9996138,0.0001439196,0.00002103272,0.00007976458,0.00004506617,0.00009634098],"domain_scores_gemma":[0.999316,0.00007908518,0.000130499,0.00005744972,0.00004477715,0.0003722776],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5799934,0.1658073,0.005656006,0.001248249,0.001180325,0.0005530264,0.0003968611,0.003542996,0.1431787,0.0006024069,0.007768483,0.09007226],"study_design_scores_gemma":[0.3528253,0.6261688,0.007129567,0.00003541289,0.0003588842,0.0002958919,0.00005705932,0.001276261,0.009182253,0.0001706094,0.002465159,0.00003479717],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886369,0.001879868,0.0008272475,0.0004054775,0.0001493955,0.003619328,0.002102865,0.0001970785,0.00218175],"genre_scores_gemma":[0.9866657,0.00141787,0.001696348,0.0007087649,0.0001927079,0.003135244,0.002521266,0.00004886417,0.003613226],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004298471,"threshold_uncertainty_score":0.01437986,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09170124266370266,"score_gpt":0.4663882106748873,"score_spread":0.3746869680111847,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}